Concepedia

Bayes‐based dosing of infliximab in inflammatory bowel diseases: Short‐term efficacy

Eugènia Santacana Juncosa, Lorena Rodríguez‐Alonso, Ariadna Padullés, Jordi Guardiola, Francisco Rodríguez‐Moranta, Katja Serra Nilsson, Jordi Bas, Francisco Morandeira Rego, Helena Colom, Núria Padullés Zamora

British Journal of Clinical Pharmacology · 2020 · 22 citations · 32 references

DOIFull text

Open access

Abstract

In our cohort of inflammatory bowel disease patients, Bayes-based optimized dosing improved the short-term efficacy of infliximab treatment.

References

32

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology · 2015 · 859 citations

, , +5

Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease

Elana Maser, Renata Villela, Mark S. Silverberg et al. · Clinical Gastroenterology and Hepatology · 2006 · 614 citations

, , +8

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

Cynthia H. Seow, Alvin Newman, Sue P. Irwin et al. · Gut · 2009 · 532 citations

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen et al. · Gut · 2013 · 451 citations

Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis

Johannan F. Brandse, Gijs R. van den Brink, Manon E. Wildenberg et al. · Gastroenterology · 2015 · 410 citations

, , +6